MXPA02011142A - Plataforma de nanodispositivo multifuncional. - Google Patents

Plataforma de nanodispositivo multifuncional.

Info

Publication number
MXPA02011142A
MXPA02011142A MXPA02011142A MXPA02011142A MXPA02011142A MX PA02011142 A MXPA02011142 A MX PA02011142A MX PA02011142 A MXPA02011142 A MX PA02011142A MX PA02011142 A MXPA02011142 A MX PA02011142A MX PA02011142 A MXPA02011142 A MX PA02011142A
Authority
MX
Mexico
Prior art keywords
therapy
multifunctional
compositions
present
nanodevice
Prior art date
Application number
MXPA02011142A
Other languages
English (en)
Inventor
James R Baker Jr
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of MXPA02011142A publication Critical patent/MXPA02011142A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/005—Dendritic macromolecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a novedosos arreglos terapeuticos y diagnosticos. De manera mas particular, la presente invencion se dirige a composiciones multifuncionales basadas en dendrimeros y sistemas para usarse en diagnostico y terapia de enfermedades (por ejemplo, diagnostico y terapia para cancer). Las composiciones y sistemas generalmente comprenden dos o mas componentes separados para enfocar, formar imagenes, sentir, y/o disparar la liberacion de un material terapeutico o diagnostico y monitorear la respuesta para terapia de una celula o tejido (por ejemplo, un tumor).
MXPA02011142A 2000-05-12 2001-05-11 Plataforma de nanodispositivo multifuncional. MXPA02011142A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/570,198 US6471968B1 (en) 2000-05-12 2000-05-12 Multifunctional nanodevice platform
PCT/US2001/015204 WO2001087348A2 (en) 2000-05-12 2001-05-11 Multifunctional nanodevice platform

Publications (1)

Publication Number Publication Date
MXPA02011142A true MXPA02011142A (es) 2004-06-22

Family

ID=24278661

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011142A MXPA02011142A (es) 2000-05-12 2001-05-11 Plataforma de nanodispositivo multifuncional.

Country Status (9)

Country Link
US (2) US6471968B1 (es)
EP (1) EP1301211A2 (es)
JP (1) JP2004515457A (es)
CN (2) CN1471407A (es)
AU (1) AU2001261420A1 (es)
BR (1) BR0110748A (es)
CA (1) CA2408535C (es)
MX (1) MXPA02011142A (es)
WO (1) WO2001087348A2 (es)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072937A1 (en) * 2001-02-10 2004-04-15 Tomalia Donald A. Nanocomposites of dendritic polymers
US6494879B2 (en) * 1998-10-15 2002-12-17 Scimed Life Systems, Inc. Treating urinary retention
US20030129654A1 (en) * 1999-04-15 2003-07-10 Ilya Ravkin Coded particles for multiplexed analysis of biological samples
US20030207249A1 (en) * 1999-04-15 2003-11-06 Beske Oren E. Connection of cells to substrates using association pairs
US20030166015A1 (en) * 1999-04-15 2003-09-04 Zarowitz Michael A. Multiplexed analysis of cell-substrate interactions
US20040018485A1 (en) * 1999-04-15 2004-01-29 Ilya Ravkin Multiplexed analysis of cells
ES2638112T3 (es) * 1999-12-16 2017-10-18 Monsanto Technology, Llc Nuevas construcciones de expresión en plantas
US20040146918A1 (en) * 2000-02-18 2004-07-29 Weiner Michael L. Hybrid nucleic acid assembly
EP1282436B1 (en) * 2000-05-19 2008-06-11 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with glp-1
JP2004537712A (ja) * 2000-10-18 2004-12-16 バーチャル・アレイズ・インコーポレーテッド 多重細胞分析システム
AU2003239368A1 (en) 2002-05-06 2003-11-17 Board Of Regents, The University Of Texas System Targeting proteins to deliver therapeutic or diagnostic reagents
US7549985B2 (en) * 2002-06-26 2009-06-23 The Regents Of The University Of Michigan Method and system to create and acoustically manipulate a microbubble
WO2004025284A1 (en) * 2002-08-29 2004-03-25 The Regents Of The University Of Michigan Laser-based method and system for enhanced optical breakdown
US7474919B2 (en) * 2002-08-29 2009-01-06 The Regents Of The University Of Michigan Laser-based method and system for enhancing optical breakdown
US7367948B2 (en) * 2002-08-29 2008-05-06 The Regents Of The University Of Michigan Acoustic monitoring method and system in laser-induced optical breakdown (LIOB)
US20050271615A1 (en) * 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
AU2003282726B2 (en) * 2002-10-03 2010-10-07 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2004041310A1 (en) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates
EP1583473A2 (en) * 2003-01-16 2005-10-12 St. Johns University New York Nanoparticle based stabilization of ir fluorescent dyes
US20070031327A1 (en) * 2003-06-03 2007-02-08 Luzzi David E Nanoradiopharmaceuticals and methods of use
US20060239907A1 (en) * 2003-06-03 2006-10-26 The Trustees Of The University Of Pennsylvania Stealthy nano agents
US20040258614A1 (en) * 2003-06-20 2004-12-23 University Of Maryland, Baltimore Microparticles for microarterial imaging and radiotherapy
US20050008861A1 (en) * 2003-07-08 2005-01-13 Nanoproducts Corporation Silver comprising nanoparticles and related nanotechnology
US7488451B2 (en) 2003-09-15 2009-02-10 Millipore Corporation Systems for particle manipulation
WO2005036180A1 (en) * 2003-10-08 2005-04-21 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Analysis methods using biomarkers concentrated with biomarkers attractant molecules
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
US20050171424A1 (en) * 2004-01-13 2005-08-04 The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services Methods for imaging the lymphatic system using dendrimer-based contrast agents
CA2567574C (en) 2004-04-08 2013-01-08 Targegen, Inc. Benzotriazine inhibitors of kinases
US20050265922A1 (en) * 2004-04-20 2005-12-01 Emory University Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
CA2567627C (en) * 2004-05-20 2014-09-30 Quest Diagnostics Investments Incorporated Single label comparative hybridization
US20070009980A1 (en) * 2004-06-01 2007-01-11 Applera Corporation Continuous fluorogenic analyte assays with dendritic amplification of signal
AU2005287375B8 (en) * 2004-08-25 2009-11-12 The Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
CA2578283A1 (en) 2004-08-25 2006-03-02 Targegen, Inc. Heterocyclic compounds and methods of use
KR100604976B1 (ko) 2004-09-03 2006-07-28 학교법인연세대학교 다작용기 리간드로 안정화된 수용성 나노입자
KR100652251B1 (ko) 2004-09-03 2006-12-01 학교법인연세대학교 다작용기 리간드를 이용한 나노입자의 표면 개질 및수용성 나노입자의 제조방법
US8354093B2 (en) 2004-10-15 2013-01-15 Washington University Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
EP2730277B1 (en) 2004-12-22 2020-03-11 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US20060269480A1 (en) * 2005-05-31 2006-11-30 Ramot At Tel Aviv University Ltd. Multi-triggered self-immolative dendritic compounds
NZ563984A (en) * 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
JP5368793B2 (ja) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
WO2007016466A2 (en) * 2005-07-29 2007-02-08 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses therefor
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US20090306198A1 (en) * 2005-09-16 2009-12-10 Robert Nicolosi Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner
MX2008005048A (es) 2005-10-18 2008-11-18 Starpharma Pty Ltd Sistema de suministro de composicion microbicidal de dendrimero.
US8566038B2 (en) * 2005-10-21 2013-10-22 The Regents Of The University Of California Compositions and methods for analyzing immobilized nucleic acids
PT1940916T (pt) 2005-10-25 2017-03-20 Starpharma Pty Ltd Composto macromolecular tendo estequiometria controlada
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
NZ567851A (en) * 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
DE112006003704A5 (de) 2005-11-25 2008-10-23 Mologen Ag DNA-Konstrukte zur spezifischen Hemmung der Genexpression durch RNA-Interferenz
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PT1959994T (pt) 2005-12-01 2017-11-30 Univ Massachusetts Lowell Nanoemulsões botulínicas
US20090317802A1 (en) * 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
CA2636599C (en) * 2006-01-20 2014-07-15 Starpharma Pty Limited Modified macromolecule
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
US8460878B2 (en) 2006-02-21 2013-06-11 The Trustees Of Tufts College Methods and arrays for detecting cells and cellular components in small defined volumes
US8193248B2 (en) 2006-03-22 2012-06-05 Starpharma Pty Limited Contraceptive composition
US7691858B2 (en) * 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
US20080070266A1 (en) * 2006-07-11 2008-03-20 Regents Of The University Of Michigan FRET-based apoptosis detector
DK2052011T3 (da) 2006-08-11 2020-12-07 Starpharma Pty Ltd Målrettet polylysin-dendrimer-terapeutisk stof
KR20150028308A (ko) 2006-12-01 2015-03-13 안테리오스, 인코퍼레이티드 펩티드 나노입자 및 이의 용도
MX2009005727A (es) 2006-12-01 2009-08-27 Anterios Inc Nanoparticulas de entidad anfifilica.
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
US20090112197A1 (en) 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US8221690B2 (en) 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US20080220434A1 (en) * 2007-02-07 2008-09-11 Perscitus Biosciences, Llc Detection Of Molecule Proximity
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20090088376A1 (en) * 2007-04-19 2009-04-02 The Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
KR100904207B1 (ko) * 2007-06-01 2009-06-25 (주) 태웅메디칼 스텐트용 약물 방출 코팅제, 그의 제조방법 및 이 코팅제로 코팅된 약물 방출 스텐트
US7507539B2 (en) 2007-07-30 2009-03-24 Quest Diagnostics Investments Incorporated Substractive single label comparative hybridization
US9175015B2 (en) 2007-08-22 2015-11-03 Colorado School Of Mines Gold nanoparticle conjugates and uses thereof
JP2010539245A (ja) 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
US8349262B2 (en) 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
EP2254901A4 (en) * 2008-02-22 2012-02-22 Inter K Pty Ltd THERAPEUTIC PEPTIDES
JP5243560B2 (ja) 2008-02-27 2013-07-24 ケーシーアイ ライセンシング インコーポレイテッド 組織部位における創傷を治療するシステムおよび方法
WO2009151687A2 (en) 2008-03-12 2009-12-17 The Regents Of The University Of Michigan Dendrimer conjugates
US8968705B2 (en) 2008-08-22 2015-03-03 Colorado School Of Mines Gold/lanthanide nanoparticle conjugates and uses thereof
US20100069821A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-sites final dosage form
US8753677B2 (en) 2008-09-16 2014-06-17 The Invention Science Fund I, Llc Ex vivo modifiable multiple medicament final dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
US9017644B2 (en) 2008-11-07 2015-04-28 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
WO2010075423A2 (en) * 2008-12-23 2010-07-01 The Regents Of The University Of Michigan Dendrimer based modular platforms
WO2011031487A2 (en) * 2009-08-25 2011-03-17 The Regents Of The University Of California Nanotechnological delivery of microbicides and other substances
WO2011028658A1 (en) * 2009-09-02 2011-03-10 The Trustees Of The University Of Pennsylvania Gadolinium-linked nanoclusters
EP2480256A4 (en) 2009-09-23 2014-06-25 Univ California CHEMICAL AMPLIFICATION RESPONSE STRATEGIES APPLYING TO MEDICAL SCIENCES
US8945508B2 (en) 2009-10-13 2015-02-03 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
CN101695476B (zh) * 2009-10-26 2011-10-19 吉林大学 医用纳米粒子的制备方法
US8912323B2 (en) 2009-10-30 2014-12-16 The Regents Of The University Of Michigan Multifunctional small molecules
WO2011072290A2 (en) * 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
WO2011090954A2 (en) 2010-01-19 2011-07-28 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
US8758778B2 (en) 2010-09-16 2014-06-24 The Regents Of The University Of California Polymeric nano-carriers with a linear dual response mechanism and uses thereof
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US10669522B2 (en) 2011-02-07 2020-06-02 Life Technologies Corporation Compositions and methods for stabilizing susceptible compounds
US9693957B2 (en) 2011-07-08 2017-07-04 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
US9402911B2 (en) 2011-12-08 2016-08-02 The Regents Of The University Of Michigan Multifunctional small molecules
CN104768538A (zh) 2012-08-28 2015-07-08 加利福尼亚大学董事会 具有光触发释放机制的聚合物纳米载体
EP2976642A4 (en) * 2013-03-15 2016-09-21 Harvard College METHODS AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR CAPTURE OF A TARGET ENTITY
EP3848044A1 (en) 2013-05-21 2021-07-14 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
JP6297440B2 (ja) * 2013-07-31 2018-03-20 キヤノンメディカルシステムズ株式会社 造影剤
EP3912986B1 (en) 2013-12-18 2023-12-13 President and Fellows of Harvard College Crp capture/detection of bacteria
CN103675288B (zh) * 2013-12-26 2015-10-28 泸州医学院 一种血小板标记物及其制备方法
RU2635557C2 (ru) 2014-01-13 2017-11-14 Хафид БЕЛХАДЖ-ТАХАР Дендримерные композиции, способы их синтеза и их применение
WO2015109255A1 (en) * 2014-01-16 2015-07-23 Genisphere, Llc Lateral flow assays using dna dendrimers
KR101566345B1 (ko) * 2014-03-21 2015-11-23 한국생명공학연구원 다가성 리간드의 내부 표면작용기와 암 표적 리간드 단위의 비율을 조절하여 암 진단 효율을 향상시키는 방법
EP3763378A1 (en) 2015-08-06 2021-01-13 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
WO2017044768A1 (en) * 2015-09-10 2017-03-16 Massachusetts Institute Of Technology Rna triple helix structures, compositions, and methods
MA39136B2 (fr) 2016-06-21 2021-04-30 Univ Euro Mediterraneenne De Fes Nouvelles macromolecules geantes : les poly - dendrimeres
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
EP3612585A4 (en) 2017-04-17 2020-12-30 University of Southern California PROCESS FOR THE PRODUCTION OF BIOCOMPATIBLE DENDRITIC POLYMERS FOR THE DETECTION OF SUBSTANCES TO BE ANALYZED WITH MULTIMODAL MARKING AND SIGNAL AMPLIFICATION
CA3106568A1 (en) * 2018-07-19 2020-01-23 Starpharma Pty Ltd Therapeutic dendrimer

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737550A (en) 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US4631337A (en) 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
US4871779A (en) 1985-12-23 1989-10-03 The Dow Chemical Company Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities
US4694064A (en) 1986-02-28 1987-09-15 The Dow Chemical Company Rod-shaped dendrimer
US4713975A (en) 1986-05-30 1987-12-22 The Dow Chemical Company Dense star polymers for calibrating/characterizing sub-micron apertures
JPS6319561A (ja) 1986-07-11 1988-01-27 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺癌単クロ−ン性抗体
DE3786000T3 (de) * 1986-08-18 1997-08-21 Dow Chemical Co Conjugate dichter Sterne.
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US5560929A (en) 1986-08-18 1996-10-01 The Dow Chemical Company Structured copolymers and their use as absorbents, gels and carriers of metal ions
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
EP0394277B1 (en) 1987-07-15 1998-01-14 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4857599A (en) 1988-02-08 1989-08-15 The Dow Chemical Company Modified dense star polymers
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH0734015B2 (ja) 1988-04-25 1995-04-12 和光純薬工業株式会社 微量成分の新規測定法
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5318529A (en) 1989-09-06 1994-06-07 Boston Scientific Corporation Angioplasty balloon catheter and adaptor
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5874218A (en) 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
ES2110444T3 (es) 1990-06-11 1998-02-16 Nexstar Pharmaceuticals Inc Ligandos de acidos nucleicos.
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5773527A (en) 1990-08-27 1998-06-30 Dendritech, Inc. Non-crosslinked, polybranched polymers
US5631329A (en) 1990-08-27 1997-05-20 Dendritech, Inc. Process for producing hyper-comb-branched polymers
US5876445A (en) 1991-10-09 1999-03-02 Boston Scientific Corporation Medical stents for body lumens exhibiting peristaltic motion
DK0627940T3 (da) 1992-03-05 2003-09-01 Univ Texas Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5354308A (en) 1992-05-01 1994-10-11 Beth Israel Hospital Association Metal wire stent
ATE187494T1 (de) 1992-12-11 1999-12-15 Dow Chemical Co Multivalente einkettige antikörper
US5387617A (en) 1993-01-22 1995-02-07 The Dow Chemical Company Small cell foams and blends and a process for their preparation
US5545532A (en) 1993-02-05 1996-08-13 Epigen, Inc. Human carcinoma antigen (HCA), HCA antibodies, HCA immunoassays and methods of imaging
CA2133967A1 (en) 1993-02-24 1994-09-01 Spencer H. Lin Immobilization of specific binding assay reagents
US5898005A (en) * 1993-02-24 1999-04-27 Dade Behring Inc. Rapid detection of analytes with receptors immobilized on soluble submicron particles
US5913894A (en) 1994-12-05 1999-06-22 Meadox Medicals, Inc. Solid woven tubular prosthesis
JP3694524B2 (ja) 1993-08-23 2005-09-14 ボストン サイエンティフィック コーポレイション 改良形バルーンカテーテル
US5609627A (en) 1994-02-09 1997-03-11 Boston Scientific Technology, Inc. Method for delivering a bifurcated endoluminal prosthesis
JPH08510761A (ja) 1994-03-07 1996-11-12 ザ・ダウ・ケミカル・カンパニー 生物活性及び／又はターゲテッドデンドリマー複合体
US5733303A (en) 1994-03-17 1998-03-31 Medinol Ltd. Flexible expandable stent
CA2189006A1 (en) 1994-04-29 1995-11-09 David L. Sandock Medical prosthetic stent and method of manufacture
US5857998A (en) 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US5620417A (en) 1994-07-07 1997-04-15 Cardiovascular Imaging Systems Incorporated Rapid exchange delivery catheter
US5755722A (en) 1994-12-22 1998-05-26 Boston Scientific Corporation Stent placement device with medication dispenser and method
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
EP0831753B1 (en) 1995-06-01 2005-12-28 Meadox Medicals, Inc. Implantable intraluminal prosthesis
US6083708A (en) * 1995-08-11 2000-07-04 Dade Behring Inc. Polypeptide: dendrimer complexes
US5795582A (en) 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers
US5792105A (en) 1996-09-11 1998-08-11 Boston Scientific Corporation Multichannel balloon catheter for delivering fluid
US5868719A (en) 1997-01-15 1999-02-09 Boston Scientific Corporation Drug delivery balloon catheter device
US5933145A (en) 1997-04-17 1999-08-03 Microsoft Corporation Method and system for visually indicating a selection query
US6143558A (en) 1997-07-08 2000-11-07 The Regents Of The University Of Michigan Optical fiberless sensors for analyzing cellular analytes
US5902863A (en) 1997-07-21 1999-05-11 Dow Corning Corporation Dendrimer-based networks containing lyophilic organosilicon and hydrophilic polyamidoamine nanoscopic domains
US5866561A (en) 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
GB9718129D0 (en) * 1997-08-27 1997-10-29 Isis Innovation Branched structures
US5908413A (en) 1997-10-03 1999-06-01 Scimed Life Systems, Inc. Radiopaque catheter and method of manufacture thereof
GB9811403D0 (en) * 1998-05-27 1998-07-22 Isis Innovation Polynucleotide multimers and their use in hybridisation assays
WO2001002861A1 (en) * 1999-06-29 2001-01-11 Dako A/S Detection using dendrimers bearing labels and probes

Also Published As

Publication number Publication date
EP1301211A2 (en) 2003-04-16
CN1471407A (zh) 2004-01-28
CA2408535A1 (en) 2001-11-22
BR0110748A (pt) 2004-08-31
JP2004515457A (ja) 2004-05-27
US6471968B1 (en) 2002-10-29
CN101347623A (zh) 2009-01-21
US20020165179A1 (en) 2002-11-07
CA2408535C (en) 2009-08-11
AU2001261420A1 (en) 2001-11-26
WO2001087348A2 (en) 2001-11-22
WO2001087348A3 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
MXPA02011142A (es) Plataforma de nanodispositivo multifuncional.
WO2006033766A3 (en) Dendrimer based compositions and methods of using the same
WO2008008483A3 (en) Dendrimer based compositions and methods of using the same
WO2009009203A3 (en) Dendrimer based compositions and methods of using the same
WO2003105757A3 (en) METHODS AND COMPOSITIONS FOR MEDIA-DEPENDENT BINDING OF A TARGET AGENT TO A TARGET
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
EP1992695A3 (en) C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
WO1997002046A3 (de) Saccharid-konjugate
RS20070365A (en) Gastroresistant pharmaceutical formulations containing rifaximin
EP2258873A3 (en) Gene expression profiling in biopsied tumor tissues
EP1016419A3 (en) Non-invasive localization of a light-emitting conjugate in a mammal
WO2006003488A3 (en) Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
EP1964850A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
CA2501719C (en) Remedy or preventive for kidney disease and method of diagnosing kidney disease
EP1708751A4 (en) METHOD OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGEN EXPOSED ON APOPTOTIC TUMOR CELLS
BG107762A (en) Radiopharmaceuticals for diagnosing alzheimer's disease
WO2005051315A3 (en) On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
WO2005048950A3 (en) Tumor and infectious disease therapeutic compositions
IL155611A0 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
WO2008067049A3 (en) Particles for cell targeting
WO2004025303A3 (en) Isoprostanes as markers of psychological stress in humans
CA2369626A1 (en) Use of cell membrane penetrating indigoid bisindole derivatives
MXPA01010186A (es) Composiciones y metodos para el tratamiento y diagnostico de cancer de mama.
EP1323732A4 (en) BETA-CATENINE NUCLEAR LOCALIZING PROTEIN